CP010
/ Complement Pharma, AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 14, 2022
Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex.
(PubMed, J Innate Immun)
- "CP010 is a promising complement C6 inhibitor that prevents MAC formation. Systemic administration of this C6 monoclonal antibody has therapeutic potential in the treatment of neuronal disease."
Journal • Preclinical • CNS Disorders • Immunology • Mood Disorders • Multiple Sclerosis • Myasthenia Gravis
1 to 1
Of
1
Go to page
1